Cite
HARVARD Citation
Sax, P. et al. (2017). Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet. 4 (4), pp. e154-e160. [Online].